摘要
目的 探讨 bcl- 2在人原发性乳腺癌中的表达及与激素受体的相关性。方法 利用免疫组织化学 (IHC)方法检测 180例人原发性乳腺癌组织中 bcl- 2的表达及与 ER、PR激素受体的相关性。结果 乳腺癌中 bcl- 2、ER和 PR的阳性符合率分别为 5 7.78% (10 4/ 180 )、5 2 .2 2 % (94/ 180 )和 38.89% (70 / 180 )。bcl- 2与 ER、PR的阳性符合率分别为94.6 8% (89/ 94)和 92 .86 % (6 5 / 70 ) ～ 级乳腺癌中 bcl-2的阳性率为 6 6 .94% ,远高于 级 38.98% (P<0 .0 1) ;>五年生存率 bcl- 2的阳性率为 70 .5 9% ,≤五年生存期的阳性率 2 9.6 3% (P<0 .0 1)。ER、PR同为阳性的五年生存率为75 % ,ER、PR两者之一阳性的其五年生存率为 6 2 .2 2 % ,与 ER、PR同为阴性五年生存率 18%相比相差显著 (P<0 .0 1) ～ 级乳腺癌 ER的阳性率为 6 4.46 % ,与 级2 7.12 %相比相差显著 (P<0 .0 1)。 bcl- 2、ER、PR的阳性表达均与乳腺癌的组织学类型、肿瘤大小、病程、淋巴结转移、年龄无相关性。结论 bcl- 2与 ER、PR一样 ,可作为乳腺癌病人预后好的一种标记物 。
Objective To investigate the bcl 2 expression and its relationship with hormone receptors in human primary breast cancers. Methods Immunohistochemical technique was used in paraffin sections of 180 cases of breast cancer, and the results of expression of bcl 2, ER and PR in breast cancer of different clinical grades were analyzed. Results bcl 2, ER and PR expressions were 57.78% (104/180), 52.22 %(94/180) and 38.89 % (70/180) respectively. In breast cancers of Ⅰ～Ⅱ grades groups the expression of bcl 2 was 66.94 %(81/121) and it was significantly higher than 30.51 %(18/59)of grade Ⅲ group ( P <0 01). bcl 2 was higher in >5 year survival group 70.59 % (48/68) than 29.63 % (16/54) in the ≤5 year survival group ( P <0 01). The 5 year survival rate was 75% in cases both ER and PR were positive, 62.22 % in cases of ER+ PR- or ER- PR+, and its was 18 % in cases of both ER and PR+negative ( P <0 01). ER expression was 64.64% (78/121) in cases of Ⅰ～Ⅱ grade groups and was higher than 27.12% (16/59) of grade Ⅲ group ( P <0 01). There was no apparent relationship between the expressions of bcl 2, ER, PR and the histologic types, tumor sizes, stages, lymph node involvement and ages of patients. Conclusion Just like ER and PR, bcl 2 expression may be an important marker of the prognosis of breast cancers.
出处
《肿瘤》
CAS
CSCD
北大核心
2000年第2期116-117,120,共3页
Tumor
